<DOC>
	<DOC>NCT02218489</DOC>
	<brief_summary>The primary purpose of this study is to determine the efficacy and safety of KPI-121 ophthalmic suspension compared to vehicle (placebo) in subjects with signs and symptoms of inflammatory meibomian gland disease.</brief_summary>
	<brief_title>Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease</brief_title>
	<detailed_description>This is a Phase II, multicenter, double-masked, randomized, vehicle-controlled, parallel-group study designed to evaluate the efficacy and safety of KPI-121 ophthalmic suspension versus vehicle in subjects with signs and symptoms of inflammatory meibomian gland disease. The product will be studied over 28 days, with 1-2 drops instilled in each eye four times daily (QID).</detailed_description>
	<mesh_term>Blepharitis</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<criteria>Have a documented clinical diagnosis of inflammatory meibeomian gland disease in both eyes. Known hypersensitivity/contraindication to study product(s) or components. Be currently receiving treatment for glaucoma, have history of or current glaucoma, or an IOP over 21mmHg at Visit 1 (Screening) or Visit 2 (Randomization). Be unwilling to discontinue warm compress therapy, lid expression, or lid massage 14 days prior to Day 1 and for the duration of the study. Diagnosis of: ongoing ocular infection; severe/serious ocular condition that in judgment of Investigator could confound study assessments or limit compliance; severe/serious systemic disease or uncontrolled medical condition that in judgment of Investigator could confound study assessments or limit compliance; or have been exposed to an investigational drug within the 30 days prior to screening. Have had ocular surgery in the past 90 days or require ocular surgery during the study. In the opinion of Investigator or study coordinator, be unwilling or unable to comply with study protocol or unable to successfully instill eye drops.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pain</keyword>
	<keyword>Corticosteroid</keyword>
	<keyword>Meibomian Gland Disease</keyword>
	<keyword>Blepharitis</keyword>
	<keyword>Eyelid</keyword>
	<keyword>Ocular Discomfort</keyword>
</DOC>